X-Zell US

X-ZELL is a biotech company that specializes in developing innovative solutions for cytology, the study of cells to diagnose diseases. The company's core business is focused on improving the efficiency and accuracy of cytological testing, particularly in the detection of cancer. X-ZELL's products and services include a range of laboratory instruments, such as the Cryofixator, Cryostainer, and Hybrid Microscope, which are designed to streamline the sample preparation and analysis process. The company's technology, including its patented Cryoimmunostaining suite, enables same-day cancer diagnoses from minimally invasive body liquids, reducing the time and manual handling required for traditional cytological testing methods. X-ZELL's goal is to make cytological testing faster, more efficient, and more accessible, ultimately leading to better diagnostics and improved patient care.

X-ZELL is a fully integrated biotechnology company specialising in rare cell detection technology.

Established in 2009 with investment from Vichit Suraphongchai – one of the leading figures in Southeast Asian banking – and support from Thailand’s premier science university, Mahidol University, X-ZELL first made headlines when it was accepted into Y Combinator’s ‘W15 Winter Batch’.

The company used the opportunity to demonstrate the utility of its technologies to reliably detect prostate cancer at an early stage, before it spreads, securing a rare Honourable Mention and funding by US start-up guru, Paul Buchheit – the creator and lead developer of Gmail – as well as six other Silicon Valley-based angel investors.

Following a successful seed round, X-ZELL opened a Silicon Valley Office in Sunnyvale, California, in 2016, which is supported by X-ZELL’s Global R&D Hub in Bangkok, Thailand.